In wet macular degeneration, blood vessels invade the space behind the retina, leading to edema, localized retinal detachment and scarring. Untreated, irreversible damage leads to vision loss.
The treatment for wet disease is anti-VEGF injections every 1-3 months, usually indefinitely. These injections can be painful, risk infection, temporarily elevate eye pressure to levels that compromise optic nerve perfusion, and are associate with retinal atrophy. Injection of steroids are equally as effective as anti-VEGF therapy however injections further increase the risk of infection and cause cataract and glaucoma.
xRMD therapy is complementary to injections of anti-VEGF medications based on published science. It lowers homocysteine which if elevated, raises VEGF and has been show to increase the risk of wet disease. Elevated homocysteine also has toxic effects on cells. One of the effects of xRMD therapy is it can silence the VEGF gene. The atherosclerosis literature also shows that epigenetics (or gene expression) can suppress VEGF.
xRMD therapy goes beyond suppressing VEGF. The list of physiological parameters that improve at the cellular level include a reduction in inflammation, a reduction in oxidative stress, and reactivation of cellular mechanisms by resolving hormonal deficiency and reprogramming gene activity. To demonstrate these ideas, read about the Lazarus case of wet disease treated with our approach.